PfMSP3 as LSP
Development of a Plasmodium falciparum vaccine based on long synthetic peptide derived from MSP3, a merozoite Surface Antigen targeted by biologically active human antibodies.
An Open Randomised Two Adjuvants, Three Doses Safety and Immunogenicity Phase Ia Clinical Trial was conducted in Lausanne. The results have been published in Infection and Immunity, December 2005, vol. 73, no.12, pages 8017-8026